IDEAL Study: Identification of the Determinants of the Efficacy of Arterial Blood Pressure Lowering Drugs

This study is currently recruiting participants.

Verified by Hospices Civils de Lyon, October 2007

First Received: August 9, 2005 Last Updated: October 3, 2007 History of Changes

Sponsored by:	Hospices Civils de Lyon
Information provided by:	Hospices Civils de Lyon
ClinicalTrials.gov Identifier:	NCT00128518

Purpose

The principal scientific objective of the trial is to identify the factors that are associated with differential blood pressure responses between drugs.

This may allow investigators to produce new hypotheses on the pathophysiology of hypertension and on the mechanisms of drug action.

These factors can be of different types:

Environmental factors (sodium or alcohol intake);
Morphological (height, weight, body mass index, body surface area);
Initial blood pressure;
Electrocardiogram (ECG) parameters of left ventricular hypertrophy;
Biological parameters as the activity level of the renin angiotensin aldosterone system;
Genetic polymorphisms.

Condition	Intervention	Phase
Hypertension	Drug: Indapamide Drug: Perindopril	Phase IV

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Efficacy Study
Official Title:	IDEAL Study : Identification of the Determinants of the Efficacy of Arterial Blood Pressure Lowering Drugs

Resource links provided by NLM:

MedlinePlus related topics: High Blood Pressure

Drug Information available for: Indapamide Perindopril Perindopril erbumine

U.S. FDA Resources

Further study details as provided by Hospices Civils de Lyon:

Primary Outcome Measures:

Blood pressure at the end of each 4 week treatment period

Estimated Enrollment:	400
Study Start Date:	October 2004

Eligibility

Ages Eligible for Study:	25 Years to 60 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Participants have to be 25 to 60 years of age
Both genders
Systolic blood pressure of 140 mmHg or above; diastolic blood pressure of 90 mmHg or above.
Cardiovascular risk must not be high, to allow for two periods of 4 weeks of placebo without ethical concern.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00128518

Contacts

Contact: François GUEYFFIER, MD

33 472 119 057

francois.gueyffier@chu-lyon.fr

Locations

France
Hôpital Louis Pradel	Recruiting
BRon, France, 69677
Contact: François GUEYFFIER, MD 33 472 119 ext 057 francois.gueyffier@chu-lyon.fr
Principal Investigator: François GUEYFFIER, MD

Sponsors and Collaborators

Hospices Civils de Lyon

Investigators

Principal Investigator:

Francois GUEYFFIER, MD

Hospices Civils de Lyon

More Information

No publications provided

Study ID Numbers:	2003.340
Study First Received:	August 9, 2005
Last Updated:	October 3, 2007
ClinicalTrials.gov Identifier:	NCT00128518 History of Changes
Health Authority:	France: Afssaps - French Health Products Safety Agency

Keywords provided by Hospices Civils de Lyon:

Hypertension - Drugs - Blood pressure response - Responders - pharmacogenetics

Study placed in the following topic categories:

Perindopril
Indapamide
Diuretics
Vascular Diseases
Angiotensin-Converting Enzyme Inhibitors

Cardiovascular Agents
Antihypertensive Agents
Protease Inhibitors
Hypertension

Additional relevant MeSH terms:

Perindopril
Indapamide
Molecular Mechanisms of Pharmacological Action
Diuretics
Physiological Effects of Drugs
Vascular Diseases
Enzyme Inhibitors
Cardiovascular Agents

Antihypertensive Agents
Pharmacologic Actions
Protease Inhibitors
Natriuretic Agents
Therapeutic Uses
Angiotensin-Converting Enzyme Inhibitors
Cardiovascular Diseases
Hypertension

ClinicalTrials.gov processed this record on July 02, 2009